By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Verastem, Inc. 

215 First Street
Suite 440
Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-858-0338 Fax: n/a


Company News
Data On Verastem (VSTM)’s Focal Adhesion Kinase Inhibitor Defactinib Presented At The 2017 AACR Annual Meeting 4/3/2017 10:43:46 AM
Verastem (VSTM) Reports Year-End 2016 Financial Results 3/24/2017 6:32:16 AM
Verastem (VSTM) To Host Conference Call On March 23rd To Discuss Fourth Quarter And Full-Year 2016 Financial Results And Recent Highlights 3/16/2017 6:35:32 AM
Verastem (VSTM) Announces Dosing Of First Patient In Combination Trial Of Defactinib And Avelumab In Patients With Ovarian Cancer 1/26/2017 11:10:37 AM
Verastem (VSTM) Release: Company Announces Executive Leadership Appointments And Changes 1/20/2017 8:03:42 AM
Verastem (VSTM) Presents Phase 2 DYNAMO Clinical Data At American Society of Hematology 2016 Annual Meeting 12/6/2016 11:19:20 AM
Verastem (VSTM) Reports Third Quarter 2016 Financial Results 11/8/2016 10:45:16 AM
Verastem (VSTM) Licenses Duvelisib From Infinity Pharma (INFI) 11/2/2016 10:48:58 AM
Verastem (VSTM) Licenses Duvelisib From Infinity Pharma (INFI) 11/2/2016 7:17:16 AM
Cancer Research UK, MSD And Verastem (VSTM) Collaborate To Trial New Combination Of Immunotherapy Drugs 9/30/2016 9:37:04 AM